GlobalData on MSN6d
Gilead’s lenacapavir applications for HIV gain EMA validation
The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
infectiousdiseaseadvisor.com18h
Twice-Yearly Lenacapavir Gets Priority Review For HIV PrEP
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Rolling Out4d
HIV breakthrough faces critical funding cuts
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
bhekisisa.org16m
The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar
The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...
Trump’s Funding Cuts Halt Rollout Of HIV Prevention Drug
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Pharmabiz6d
EMA validates Gilead’s MAA and EU-Medicines for all application for twice-yearly lenacapavir for HIV prevention
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
Yahoo Finance6d
Morgan Stanley sees FDA approval of GILD's Lenacapavir
“We continue to see upside to GILD's Lenacapavir (LEN) launch for HIV prevention,” Morgan Stanley analysts wrote, estimating 2025 U.S. sales of $184 million, well above the $111 million ...